Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03282240 · ClinicalTrials.gov registry record · Phase 3
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
A Phase 3 study, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,670
- Enrollment target
NCT03282240 is a Phase 3 study that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 2,670 participants.
The verdict
NCT03282240, a Phase 3 study, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,670 participants
- Enrollment target
Study Summary
This randomized, modified double-blind, active-controlled, multi-center trial assessed the safety and immunogenicity of the high-dose quadrivalent influenza vaccine (QIV-HD) compared to either the licensed or investigational high-dose trivalent influenza vaccine (TIV-HD) in adults.
Interventions
- BIOLOGICAL QIV-HD
- BIOLOGICAL Licensed TIV-HD1
- BIOLOGICAL Investigational TIV-HD2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,670 participants |
| Start Date | 2017-09-08 |
| Est. Completion | 2018-04-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03282240
The ClinicalTrials.gov registry entry for NCT03282240 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,670 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which QIV-HD is the first listed.
NCT03282240 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03282240 about?
NCT03282240 is a clinical study titled "Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US". This randomized, modified double-blind, active-controlled, multi-center trial assessed the safety and immunogenicity of the high-dose quadrivalent influenza vaccine (QIV-HD) compared to either the licensed or investigational high-dose trivalent influenza vaccine (TIV-HD) in adults.
What is the current status of trial NCT03282240?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,670 participants. The study started on 2017-09-08. Estimated completion is 2018-04-19.
What interventions are being tested in trial NCT03282240?
The interventions under investigation include: QIV-HD (BIOLOGICAL), Licensed TIV-HD1 (BIOLOGICAL), Investigational TIV-HD2 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03282240?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.